CL
DMAAR

CSS LLC’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

CSS LLC’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.5K Hold
31,250
– – ﹤0.01% 944
2026
Q1 		$15.1K Hold
31,250
– – ﹤0.01% 921
2025
Q4 		$46.8K Hold
31,250
– – ﹤0.01% 910
2025
Q3 		$54.4K Buy
+31,250
New +$5.81K ﹤0.01% 894

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

CSS LLC's DMAAR Position: Q2 2026 in Review

CSS LLC held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 31,250 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #944.

CSS LLC first reported a position in DMAAR in Q3 2025 and has held it in 4 quarters since. The position peaked at $54.4K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • CSS LLC held 31,250 shares of Drugs Made In America Acquisition Corp Rights worth $27.5K as of Q2 2026.
  • CSS LLC left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of CSS LLC's portfolio in Q2 2026, its #944 holding.
  • CSS LLC first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 4 quarters since.
  • CSS LLC's Drugs Made In America Acquisition Corp Rights position peaked at $54.4K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.